Cereno Scientific Secures SEK 100m in Directed Share Issue and SEK 350m Loan Financing, Targeting Milestones by Q4 2027
Cereno Scientific has secured SEK 100 million through a directed share issue and an additional SEK 350 million in loan financing.
The financing supports the company's growth and advancement toward key milestones expected by the fourth quarter of 2027.
Cereno Scientific is advancing a pioneering pipeline focused on HDAC inhibitors for rare cardiovascular and pulmonary diseases, including pulmonary arterial hypertension (PAH).
The company is progressing multiple clinical programs, including CS1 and CS014, aiming at disease-modifying therapies with positive Phase I data supporting further development.
The funding will strengthen the company’s financial position to accelerate clinical trials and development activities in the coming years.
This strategic financial move aligns with Cereno’s commitment to rare disease treatments that have shorter development timelines and significant unmet medical needs.
Milestones targeted by Q4 2027 likely include progress in clinical trials and regulatory achievements for their drug candidates.